sired target and epileptogenic zone, in conjunction with live feedback of the tissue ablation and monitoring of the surrounding tissue. In 2012, Dr. Daniel Curry published the first case series of MRgLITT in pediatric epilepsy, treating 2 hypothalamic hamartoma patients, and 3 patient with focal cortical dysplasia, mesial temporal sclerosis, and cingulate tuber due to tuberous sclerosis (1 case of each), with encouraging albeit early results. 1 Miami Children's Hospital followed with their results for MRgLITT in 2015, treating primarily focal cortical dysplasia (12 of 21 lesions), but including 5 patients with tubers associated with tuberous sclerosis. 4 They demonstrated a 47% rate of Engel class I/II outcomes. As MRgLITT was proving to be a safe and effective treatment option, the applications expanded, including corpus callosotomy. 3 Dr. TovarSpinoza published the first series of pediatric brain tumors treated with MRgLITT in 2016. 5, 6 Previously, patients with multiple epileptogenic foci (e.g., in tuberous sclerosis) had been excluded from epilepsy surgery, even when they had DRE. Although over 80% of patients with tuberous sclerosis have DRE, only about one-third of these patients become surgical candidates. In this case series, Dr. Tovar-Spinoza demonstrates the potential of MRgLITT to treat cortical tubers in single or staged approaches for children with DRE. 7 Lesionectomy and tuberectomy, including ablation of the perituberal area, achieved seizure freedom in over 50% of patients with a mean follow-up of 19 months. Furthermore, MRgLITT offers the possibility of surgical treatment as early as the epileptogenic focus or tubers are identified without excluding the option for further MRgLITT if other tubers become active in the future. The major benefit of minimally invasive procedures is the reduction in the morbidity associated with open surgery, as this specific case series reported no complications. Unfortunately, there is little data on complications in children treated with MRgLITT. These promising results ensure a place for MRgLITT in the armamentarium of every pediatric neurosurgeon. As we go forward, prospective multicenter studies are critically needed to define the optimal candidates for MRgLITT and timing of the procedure(s), analyze the durability of short and long-term outcomes, and better define potential complications. Only then will we know which patients and lesions may be best suited for open surgery versus ablation.
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